Cellectis Today CLLS Cellectis $1.38 -0.07 (-4.83%) 52-Week Range $1.10 ▼ $3.38 Price Target $7.00 Add to Watchlist Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology. Following a substantial strategic equity investment from AstraZeneca NASDAQ: AZN and a strengthened financial position reported in its full-year 2024 results, Cellectis has entered a potentially pivotal stage in its market narrative. ...